tubeimoside i
Recently Published Documents


TOTAL DOCUMENTS

30
(FIVE YEARS 4)

H-INDEX

8
(FIVE YEARS 0)

2021 ◽  
Vol 2021 ◽  
pp. 1-22
Author(s):  
Dingyi Lv ◽  
Minghao Luo ◽  
Zhe Cheng ◽  
Ruiyu Wang ◽  
Xiyang Yang ◽  
...  

Myocardial ischemia-reperfusion injury (MIRI) is a phenomenon that reperfusion leads to irreversible damage to the myocardium and increases mortality in acute myocardial infarction (AMI) patients. There is no effective drug to treat MIRI. Tubeimoside I (TBM) is a triterpenoid saponin purified from Chinese traditional medicine tubeimu. In this study, 4 mg/kg TBM was given to mice intraperitoneally at 15 min after ischemia. And TBM treatment improved postischemic cardiac function, decreased infarct size, diminished lactate dehydrogenase release, ameliorated oxidative stress, and reduced apoptotic index. Notably, ischemia-reperfusion induced a significant decrease in cardiac SIRT3 expression and activity, while TBM treatment upregulated SIRT3’s expression and activity. However, the cardioprotective effects of TBM were largely abolished by a SIRT3 inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP). This suggests that SIRT3 plays an essential role in TBM’s cardioprotective effects. In vitro, TBM also protected H9c2 cells against simulated ischemia/reperfusion (SIR) injury by attenuating oxidative stress and apoptosis, and siSIRT3 diminished its protective effects. Taken together, our results demonstrate for the first time that TBM protects against MIRI through SIRT3-dependent regulation of oxidative stress and apoptosis. TBM might be a potential drug candidate for MIRI treatment.


2021 ◽  
pp. 174186
Author(s):  
Zhe Cheng ◽  
Dingyi Lv ◽  
Minghao Luo ◽  
Ruiyu Wang ◽  
Yongzheng Guo ◽  
...  

Author(s):  
Xiyang Yang ◽  
Xingbing Li ◽  
Minghao Luo ◽  
Chang Li ◽  
Longxiang Huang ◽  
...  

2021 ◽  
Vol 267 ◽  
pp. 113642
Author(s):  
Xiyang Yang ◽  
Xingbing Li ◽  
Minghao Luo ◽  
Yongzheng Guo ◽  
Chang Li ◽  
...  

Author(s):  
Juan Du ◽  
Zhen Dong ◽  
Li Tan ◽  
Mengqin Tan ◽  
Fang Zhang ◽  
...  

Tubeimoside I (TBMS1), also referred to as tubeimoside A, is a natural compound extracted from the plant Tu Bei Mu (Bolbostemma paniculatum), which is a traditional Chinese herb used to treat multiple diseases for more than 1,000 years. Studies in recent years reported its anti-tumor activity in several cancers. However, whether it is effective in melanoma remains unknown. In the current study, we discovered that TBMS1 treatment inhibited melanoma cell proliferation in vitro and tumorigenecity in vivo. Besides, we also observed that TBMS1 treatment induced a partly disrupted autophagy, which still remained a protective role, disruption of which by chloroquine (CQ) or 3-methyladenine (3-MA) enhanced TBMS1-induced cell proliferation inhibition. CQ combined with TBMS1 even induced cellular apoptosis. BRAF(V600E) mutation and its continuously activated downstream MEK1/2-ERK1/2 cascade are found in 50% of melanomas and are important for malanomagenesis. However, hyperactivating MEK1/2-ERK1/2 cascade can also inhibit tumor growth. Intriguingly, we observed that TBMS1 rapidly hyperactivated MEK1/2-ERK1/2, inhibition of which by its inhibitor SL-327 rescued the anti-cancerous effects of TBMS1. Besides, the targets of TBMS1 were predicted by the ZINC Database based on its structure. It is revealed that protein-tyrosine phosphatase 1B (PTP1B) might be one of the targets of TBMS1. Inhibition of PTP1B by its selective inhibitor TCS401 or shRNA rescued the anti-cancerous effects of TBMS1 in melanoma cells. These results indicated that TBMS1 might activate PTP1B, which further hyperactivates MEK1/2-ERK1/2 cascade, thereby inhibiting cell proliferation in melanoma. Our results provided the potentiality of TBMS1 as a drug candidate for melanoma therapy and confirmed that rapidly hyperactivating an oncogenic signaling pathway may also be a promising strategy for cancer treatment.


2020 ◽  
Vol 11 (8) ◽  
Author(s):  
Kun Wang ◽  
Yujuan Zhan ◽  
Bonan Chen ◽  
Yuhua Lu ◽  
Ting Yin ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Silin Liu ◽  
Xianmei Pan ◽  
Wenbin Cheng ◽  
Bo Deng ◽  
Yu He ◽  
...  

2020 ◽  
Vol 80 ◽  
pp. 106202 ◽  
Author(s):  
Mingli Yang ◽  
Jian Xie ◽  
Xiaocan Lei ◽  
Zhifu Song ◽  
Yadong Gong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document